Hi all, medicinal chemist here to clear up some confusion. First and foremost, this product is being labeled as (r)-MDMA but let's be clear, the product in question is 2-(p-tolyl)-cyclopropylamine (CAS #90874-49-0 as the HCl salt).
Second, people here are screaming about the toxicity of cyclopropane groups. This is categorically incorrect. A number of drugs (Livalo and moxifloxacin immediately come to mind) have cyclopropane rings and exhibit no significant toxicity related to this functional group. Someone mentioned alkylation of DNA which is completely untrue. The nitrogen mustards utilize reactive aziridine rings to alkylate DNA, not cyclopropane rings
As far as MAOI risk, you cannot simply say "oh, well the demethylated derivative is an MAOI so this probably will be too." The fact of that matter is if you're willing to take the obscene risk of snorting a bunch of chemicals synthesized in China, no one can make an educated guess whether this one is more or less toxic than anything else you've put up your nose. The fact of that matter is there is literally zero tox research into any research chemicals. The only data we have are medical case reports when someone presents to the emergency room.
For the wanna-be chemists in the group, para hydroxylation is a major route of metabolism (and eventual excretion) and blocking this action by p-methylation radically alters the pharmacokinetics of the drug. In addition, this can radically alter the enzyme binding affinity and it would not surprise me at all for this compound to have substantially different MAOI activity (higher or lower) than trans-2-phenyl-cyclopropylamine (the original compound in question).
It absolutely amazes me how much misinformation makes its way onto this site. Hopefully everyone takes what's said here with a HUGE grain of salt.